Categories : Endocrine & Metabolic
Product Packaging : 10 / 30 tablets
Product Composition : 1 mg + 15 mg + 500 mg, 2 mg + 15 mg + 500 mg
Send MessageGlimepiride + Pioglitazone + Metformin ER Tablets represent an advanced triple-drug formulation designed for comprehensive management of type 2 diabetes mellitus by targeting multiple metabolic pathways simultaneously. This combination integrates Glimepiride to stimulate insulin release, Pioglitazone to enhance peripheral insulin sensitivity through PPAR-gamma activation, and Metformin ER (extended-release) to suppress hepatic glucose production and improve glucose utilization.
The inclusion of Metformin in extended-release form ensures gradual absorption and sustained therapeutic levels, while Pioglitazone works on insulin resistance at the cellular level, making this formulation particularly beneficial in insulin-resistant patients. This triple therapy is widely prescribed in patients who require intensified glucose control beyond dual-drug regimens.
Genliva Wellness LLP, Himatnagar, India, is a dependable glimepiride pioglitazone metformin ER tablet manufacturer India, supplying high-quality antidiabetic combinations aligned with international regulatory and export standards.
Glimepiride + Pioglitazone + Metformin ER Tablets are triple-combination antidiabetic medications designed to provide comprehensive and extended blood glucose control in type 2 diabetes mellitus. The extended-release formulation supports prolonged therapeutic action and improved metabolic management.
These tablets are commonly used for the treatment of type 2 diabetes mellitus in adults when single or dual therapy is inadequate. They help improve glycemic control along with diet and exercise support.
Glimepiride + Pioglitazone + Metformin ER Tablets provide multi-targeted glucose control with enhanced metabolic support and improved patient convenience for effective diabetes management.
